Biotalys has secured €12.05m in fresh capital through a private placement, in a move that underscores growing investor support in Europe and the US for safe, efficacious and increasingly cost-competitive biological crop protection solutions.
The Belgian agtech company, which develops protein-based biocontrols, raised the funds from existing institutional investors including Ackermans & van Haaren, Gimv, PMV, Sofinnova Industrial Biotech and the Flemish Institute for Biotechnology (VIB). The placement represents a roughly 21% increase in issued shares and was priced at €1.53 per share.
The financing comes at a time when investment in biologicals is becoming more focused but increasingly strategic, with investors backing platforms that can combine the performance of synthetic chemistry with improved environmental profiles.
The raise also comes after Biotalys announced that it has achieved a first research milestone in its partnership with Syngenta to develop a novel bioinsecticide targeting key insect pests. It follows initial laboratory (in vitro) tests, which demonstrated promising results for new bioactive ingredients developed using Biotalys’ proprietary AGROBODY™ technology. These bioactives showed activity against a specific insect molecular target.
Biologicals gain traction as chemistry faces pressure
Biotalys’ raise reflects a broader shift in capital allocation across the agri-input sector, where regulatory pressure, sustainability targets and evolving market demands are reshaping crop protection strategies.
Chairman Simon Moroney said the funding reflects a growing recognition of the role biologicals will play in future farming systems.
“There’s an urgent and growing need for safe, efficacious and cost-competitive biocontrol solutions,” he said, adding that fermentation-based technologies are “essential to the future of sustainable crop protection”.
While such technologies are often positioned as potential alternatives to synthetic inputs, industry consensus increasingly points to a more nuanced reality: biocontrols are currently being deployed primarily as complements within integrated pest management systems, rather than outright substitutes for chemistry.
From science to scale: a more disciplined funding environment
The funding round also highlights how investor behaviour in agtech has evolved following the sector’s broader capital reset.
Rather than backing speculative early-stage biology plays, investors are increasingly focusing on scalable platforms, clear regulatory pathways and commercial manufacturing potential.
Biotalys’ proposition, bridging the efficacy of conventional chemistry with the environmental advantages of biologicals, aligns closely with these criteria.
The company’s AGROBODY™ platform uses engineered proteins to target crop pests and diseases across pre- and post-harvest applications, positioning it within a cohort of companies aiming to deliver precision biologicals at industrial scale.
Pipeline focus: advancing toward commercial validation
Proceeds from the private placement will be directed toward advancing the company’s pipeline, with particular emphasis on its lead biofungicide programmes: EVOCA™ / EVOCA NG and BioFun-6.
Funding will support ongoing field trials, regulatory submissions in the EU and US, manufacturing scale-up and continued development of its AGROBODY Foundry™ platform.
Key near-term milestones include EU regulatory approval for EVOCA and product registration in California, both seen as critical inflection points for commercialisation.
